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ABSTRACT
Reproductive history and exogenous hormonal exposures are acknowledged risk 
factors for breast cancer in the general population. In women at increased breast 
cancer risk for genetic predisposition or positive family history, data regarding these 
risk factors are limited or conflicting, and recommendations for these categories 
are unclear. We evaluated the characteristics of reproductive life in 2522 women at 
increased genetic or familial breast cancer risk attending our Family Cancer Center. 
Breast cancers in BRCA mutation carriers were more likely to be hormone receptor 
negative, diagnosed at 35 years or before and multiple during the lifetime than 
tumors in women at increased familial risk, while the distribution of invasive cancers 
and HER2 positive tumors was similar in the different risk groups. At least one full-
term pregnancy (HR 0.27; 95% CI 0.12–0.58; p = 0.001), breastfeeding either less 
(HR 0.24; 95% CI 0.09–0.66; p = 0.005) or more (HR 0.25; 95% IC 0.08–0.82;  
p = 0.022) than one year and late age at menopause (HR 0.10; 95% CI 0.01–0.82; 
p = 0.033) showed to be protective factors in BRCA mutation carriers, while in 
women at increased familial risk early age at first full-term pregnancy (HR 0.62; 95% 
IC 0.38–0.99; p = 0.048) and late menarche (HR 0.61; 95% CI 0.42–0.85; p = 0.004) 
showed to be the main protective factors. Finally, for the entire population, combined 
hormonal contraceptives demonstrated to do not increase breast cancer risk. The 
results of our study suggest that women at high familial risk and mutation carries 
develop tumors with different clinical-pathological characteristics and, consequently, 
are influenced by different protective and risk factors. 
INTRODUCTION
Breast cancer (BC) represents the most common 
form of cancer and the leading cause of cancer death 
among women worldwide, with an estimated 1.7 million 
cases and 521,900 deaths in 2012. BC alone accounts 
for 25% of all cancer cases and 15% of all cancer deaths 
among females [1]. 
In the general population, acknowledged risk factors 
for BC are aging, white race, reproductive history (i.e. early 
menarche, late menopause, nulliparity, late age at first 
birth, no breastfeeding), exposures (i.e. exogenous 
hormones like combined hormonal contraceptives (CHCs) 
or hormone replacement therapy), alcohol, tobacco 
smoking, overweight and obesity, lack of exercise, dense 
breast tissue, previous chest radiation, precancerous 
lesions, personal history of BC, family history and 
mutations in BC predisposition genes (BRCA1, BRCA2, 
PALB2, PTEN, CHEK2, etc.) [2–13]. 
These risk factors have also been investigated in 
the high-risk population of BRCA mutation carriers in 
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a variety of studies. Particularly, a recent meta-analysis 
[14] showed that, in BRCA1-mutation carriers, the only 
factor that both provided sufficient evidence from the 
grading analysis and for which a meta-analysis could 
be derived, was the protective effect of late age at first 
birth. This is inconsistent with the effect in the general 
population. On the other hand, no reproductive factor 
was unequivocally associated with risk modification in 
BRCA2-mutation carriers. Interestingly, meta-analysis 
of case-control studies of oral contraceptives use in 
mutation carriers resulted in no association with BC risk. 
In contrast, meta-analysis of prospective cohort studies 
indicated an increase in BC risk among mutation carriers. 
Therefore, different study designs revealed conflicting 
results and most of the associations were deficient in one 
or more ways. Nevertheless, the authors concluded that, 
despite the limitations of the data available to address 
which factors are associated with cancer risk, many of 
the associations are largely consistent with the effects 
that would be predicted in the general population [14]. 
For what concerns women at increased familial risk with 
unknown mutation status, the data available are even more 
limited and conflicting.  
In conclusion, it results unclear the extent to 
which these modifiers of risk influence BC risk in BRCA 
mutation carriers and in women with a family history of 
BC. Nonetheless, an accurate risk assessment in these 
high-risk populations remains fundamental, in order to 
establish personalized strategies for risk control (i.e. 
surveillance, chemoprevention [15] and prophylactic 
surgery [16]). At this aim, reproductive factors were 
investigated in a population of Italian women attending 
the Modena Family Cancer Clinic (MFCC), comparing 
women classified at different levels of increased BC risk.
RESULTS
We collected the main reproductive factors through 
the revision of the medical records of 2527 women 
attending the MFCC between May 2010 and January 
2016. One woman with a MLH1 mutation and 4 women 
who underwent bilateral prophylactic mastectomy have 
been subsequently excluded, thus 2522 women were 
finally analyzed. Characteristics of the entire population 
divided by subgroups and the distribution of reproductive 
variables are presented in Table 1. The characteristics 
of reproductive life were homogeneous among the three 
groups, except for nulliparity that was significantly more 
frequent in the mutation carriers (p < 0.001). 
The mean age ± SD of the entire population at 
the end of the period was 52 ± 13 years, ranging from 
17 years to 92 years. Among these women, 113 (5%) had 
a pathogenic mutation in one of the BRCA genes (VHR 
Group). The mean age for the mutation carriers at the end 
of the period was 51 ± 14, years and they were 64 BRCA1 
and 49 BRCA2. In addition, 1541 (61%) were at High Risk 
(HR) with a mean age of 52 ± 13 years and 868 (34%) 
women were at Intermediate Risk (IR) with a mean age of 
52 ± 12 years, according to the Modena criteria. Fourteen 
women with a BRCA variant of unknown significance 
(VUS) have been classified according to their family 
history (2 at Intermediate Risk and 12 at High Risk). 
Overall, 255 women developed BC during their 
lifetime, at a median age of 48 years (SD 11, range 18–87). 
One hundred and sixty-three of these women developed 
BC before the first access at the MCFF. The Modena 
Criteria correctly identified 3 different categories at 
increasing cumulative BC risk (p < 0.001) (Figure 1).
The characteristics of tumors developed by each 
group are summarized in Table 2. Particularly, BCs in 
BRCA carriers were more likely to be hormone receptor 
negative (p = 0.024), diagnosed at 35 years or before 
(p = 0.002) and multiple during the lifetime (p = 0.017). 
Consequently, age at diagnosis was significantly lower 
in VHR compared to HR and IR (44 vs. 49 vs. 50 years, 
respectively) (p = 0.007). On the contrary, the distribution 
of invasive BC (p = 0.338) and HER2 positive tumors 
(p = 0.545) was similar in the three groups of patients. 
Nevertheless, it should be noted that BRCA1-related BC 
were significantly more likely to be hormone receptor 
negative than BRCA2-related tumors (p = 0.036). 
Moreover, somewhat surprisingly, we found a higher rate 
of HER2-negative tumors than that seen in the general 
population for all the three groups at increasing risk 
(respectively, 87%, 91% and 96%). 
The cumulative risks at 60 years according to the 
characteristics of reproductive life and CHCs use for each 
risk category are presented in Table 3.
Effect of pregnancy
Among BRCA mutation carriers, women with at 
least one full-term pregnancy compared with nulliparous 
women had a lower risk of BC (p = 0.001). In order 
to avoid the potential bias due to BC detected before 
pregnancy, in this analysis we included women that 
developed cancer before getting pregnant in the group of 
nulliparous. Notably, among parous women, an increasing 
number of full-term pregnancies seem to be associated 
with a decrease in BC risk (HR for 1 pregnancy = 0.31, 
HR for 2 pregnancies = 0.29, HR for 3 or more 
pregnancies = 0.08). Interestingly, only in HR group, age 
at first live birth ≤ 30 showed to significantly reduce risk 
for BC (p = 0.048). 
Effect of breastfeeding
We observed no association between ever having 
breast-fed and BC risk, among women at increased familial 
risk (HR and IR groups). In these two groups, there was 
also no statistically significant association between duration 
of breastfeeding (more or less than 12 months) and BC 
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risk. Interestingly, only in VHR group, breastfeeding either 
less (p = 0.005) or more (p = 0.022) than one year showed 
to significantly reduce the risk for BC.
Effect of miscarriage or abortion
We found no association between having a 
miscarriage or abortion and the risk of BC for the VHR 
group (p = 0.384) and for the HR group (p = 0.987). 
Conversely, in the IR group a miscarriage or an abortion 
seems to have increased the risk of BC (p = 0.018).
Effect of menarche and menopause
In HR women, a late age at menarche (> 12 years) 
showed to significantly reduce risk for BC (p = 0.004). 
For the analysis of menopausal age, we’ve considered only 
women diagnosed after their menopause. Interestingly, late 
menopause (> 50 years) seems to be even protective in 
BRCA mutation carriers (p = 0.033). 
Effect of use of combined hormonal 
contraceptives (CHC)
The current or past use of CHC did not show to 
significantly modify risk for BC in all the risk groups. 
Particularly, BC risk was not influenced by CHC duration 
of assumption and also an assumption longer than 10 years 
did not increase BC risk in all the groups.
DISCUSSION
Reproductive history and exogenous hormonal 
exposures are acknowledged risk factors for BC in general 
population [2–13]. Nevertheless, in women at increased BC 
risk for genetic predisposition or positive family history, 
Figure 1: (A) Cumulative Nelson-Aalen hazard by risk groups according to the combination of Tyrer-Cuzick model and 
the Modena Criteria; (B) Cumulative Nelson-Aalen hazard by risk groups according to the Modena criteria. Comparison of 
discriminant power (c-Harrell, AUC).
Oncotarget4www.impactjournals.com/oncotarget
data regarding these risk factors are limited or conflicting, 
and recommendations for these categories are unclear. 
On these bases, we decided to carry out an observational 
retrospective study among women at increased genetic 
or familial BC risk attending our Institution, one of the 
largest and most specialized Family Cancer Clinic in Italy. 
Characteristics of reproductive life have been evaluated in 
2522 women according to their risk profile. Women have 
been classified according to the Modena Criteria [17, 18], 
which demonstrated to be able to correctly stratify the risk 
in women with a family history of breast cancer. 
In the present study, we found that at least one 
full-term pregnancy represents a protective factor for BC 
in VHR group, and an increasing number of full-term 
pregnancies is associated with a proportional decrease in 
BC risk. On the other hand, age at first full-term pregnancy 
≤ 30 years showed to be a protective factor only in women 
at high familial risk for BC (HR Group). In previous 
Table 1: Characteristics of the entire population by divided subgroups and the distribution of 
reproductive variables
VHR Group HR Group IR Group p-value
N° of women 113 1541 868
Mean age (SD) 51 (14) 52 (13) 52 (12) 0.634
Pregnancy (%) (2094 women)
Yes 59 (69) 1100 (86) 618 (85) < 0.001
No 26 (31) 180 (14) 111 (15)
N° of pregnancies (%) (1777 women)
1 18 (30) 493 (45) 276 (45) 0.271
2 34 (58) 509 (46) 288 (47)
3+ 7 (12) 98 (9) 54 (9)
Age at first full term pregnancy (%) (1725 women)
≤ 30 years 42 (78) 829 (77) 446 (74) 0.304
> 30 years 12 (22) 241 (23) 155 (26)
Breastfeeding (%) (926 women)
Pregnancy without 
breastfeeding
7 (17) 104 (19) 49 (15) 0.300
1–12 months 20 (49) 295 (53) 171 (51)
> 12 months 14 (34) 154 (28) 112 (34)
Menarche (%) (2522 women)
≤ 12 years 73 (65) 893 (58) 493 (57) 0.285
> 12 years 40 (35) 648 (42) 375 (43)
Menopause (%) (359 women)
≤ 50 years 8 (53) 144 (59) 56 (57) 0.868
> 50 years 7 (47) 101 (41) 43 (43)
Abortion (%) (1078 women)
Yes 13 (25) 171 (29) 125 (29) 0.762
No 40 (75) 428 (71) 301 (71)
CHC use (%) (1467 women)
Present/Previous 41 (58) 604 (69) 373 (71) 0.060
Never 30 (42) 270 (31) 149 (29)
CHC Duration (%) (1457 women)
≤ 10 years/no use 65 (92) 739 (86) 446 (87) 0.139
> 10 years 6 (8) 135 (15) 66 (13)
Statistical test: one-way ANOVA for age; for categorical variables chi2 test or Fischer’s exact test, when appropriate.
VHR = Very High Risk, HR = High Risk, IR = Intermediate Risk, SD = Standard Deviation.
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literature, age at first full-term pregnancy demonstrated 
to be a powerful denominator of future BC risk in the 
general population, as it determines the length of time 
the undifferentiated breast tissue remains particularly 
vulnerable [19–21]. Interestingly, it has been reported that 
older age at first full-term pregnancy has also an impact on 
the molecular subtypes of BC and, it has been associated 
with increased risk for luminal BC and lobular histotype 
[4, 22–24]. In our BRCA mutated subjects, the association 
between early first full-term pregnancy and decreased 
BC risk was not significant, as also reported in previous 
research [14]. This finding could be explained by the 
fact that BRCA carriers tend to develop more frequently 
hormone receptor negative tumors, while age at first full-
term pregnancy seems to modify mostly the incidence of 
hormone receptor positive tumors [4, 22–24].
After pregnancy, an extended period of 
breastfeeding contributes to the functional ripening of 
the glandular tissue. On these bases, the duration of 
breastfeeding is believed to have an influence on BC 
risk. Particularly, the Collaborative Group on Hormonal 
Factors in Breast Cancer found that the RR for BC 
decreased by 4.3% (p < 0.0001) for every 12 months of 
breastfeeding [3]. Interestingly, a recent workshop on 
postpartum remodeling, lactation, and BC risk held by the 
National Cancer Institute suggested a particular protection 
against triple-negative, basal-like, and BRCA1 mutation-
associated BC [25]. Moreover, two recent meta-analyses 
confirmed the protective effect of ever breastfeeding 
against hormone receptor-negative BC, which are more 
common in younger women and BRCA mutation carriers 
[24, 26]. Our results confirm these previous findings, 
since we found a protective effect of breastfeeding only in 
BRCA mutation carriers that, also in our sample, are more 
likely to be affected by hormone receptor negative BC.
As regards the effects of previous miscarriages/
abortions, a collaborative reanalysis including 83,000 
women with BC showed that miscarriages and abortions 
do not increase BC risk [27] and the same was found 
In Chinese women, specifically for abortion [28]. On 
the other hand, in BRCA mutation carriers data on the 
association between incomplete pregnancies and a higher 
BC risk are conflicting [29, 30]. Our results showed that 
miscarriages and abortions increase the risk of BC only 
in the IR group. These findings should be confirmed in 
larger samples and with the evaluation of other cofounders 
such as total months of these pregnancies and age at 
miscarriage/abortion.
In 2012, a meta-analysis including 118,964 women 
with invasive BC and 306,091 without the disease, 
showed that BC risk increases by a factor of 1.050 (95% 
CI 1.044–1.057) for every year younger at menarche, 
and independently by a smaller amount (1.029; 95% 
CI 1.025–1.032), for every year older at menopause. 
Particularly, exposure to endogenous ovarian hormones 
are more relevant for estrogen receptor positive disease 
than for estrogen receptor negative disease and for lobular 
than for ductal tumors [4, 5]. In our study, a late age at 
Table 2: The characteristics of tumors developed by each risk group
VHR Group HR Group IR Group p-value
N° of BC (255 patients) 45 (40) 160 (10) 50 (6) < 0.001
Mean age (SD) 44 (11) 49 (11) 50 (10) 0.007
HER2 status (%) (143 patients)
Positive 1 (4) 8 (9) 4 (15) 0.545
Negative 24 (96) 80 (91) 26 (87)
Hormone Receptor Status (%) (174 patients)
Positive 21 (60) 88 (83) 25 (76) 0.024
Negative 14 (40) 18 (17) 8 (24)
Age at diagnosis (%) (248 patients)
≤ 35 years 9 (20) 16 (10) 0 0.002
> 35 years 35 (80) 139 (90) 49 (100)
Invasive Carcinoma (%) (225 patients)
Yes 34 (85) 108 (78) 33 (72) 0.338
No 6 (15) 31 (22) 13 (28)
Multiple Carcinoma in the lifetime (%) (247 patients)
Yes 10 (23) 11 (7) 4 (8) 0.017
No 34 (77) 144 (93) 44 (92)
Statistical test: one-way ANOVA for age; for categorical variables chi2 test or Fischer’s exact test, when appropriate.
VHR = Very High Risk, HR = High Risk, IR = Intermediate Risk, BC = Breast Cancer, SD = Standard Deviation.
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Table 3: The cumulative risks at 60 years according to the characteristics of reproductive life and 
oral contraception for each risk category
Hazard Ratio 95% CI p-value
Pregnancy, yes
VHR 0.27 0.12–0.58 0.001
HR 0.94 0.43–2.02 0.869
IR 1.00 0.31–3.29 0.999
N° of pregnancies, 1
VHR 0.31 0.12–0.85 0.022
HR 0.84 0.37–1.87 0.662
IR 0.75 0.22–2.63 0.650
N° of pregnancies, 2
VHR 0.29 0.12–0.66 0.003
HR 0.99 0.45–2.18 0.975
IR 1.09 0.32–3.69 0.885
N° of pregnancies, 3
VHR 0.08 0.01–0.67 0.019
HR 1.17 0.46–2.99 0.740
IR 1.80 0.45–7.20 0.407
Age at first full term pregnancy, ≤ 30 years
VHR 0.49 0.19–1.26 0.138
HR 0.62 0.38–0.99 0.048
IR 0.61 0.29–1.32 0.213
Breastfeeding, 1–12 months
VHR 0.24 0.09–0.66 0.005
HR 1.12 0.49–2.58 0.784
IR 1.49 0.42–5.22 0.536
Breastfeeding, > 12 months
VHR 0.25 0.08–0.82 0.022
HR 1.91 0.79–4.61 0.151
IR 1.86 0.49–7.03 0.357
Menarche, > 12 years 
VHR 1.23 0.67–2.25 0.504
HR 0.61 0.42–0.85 0.004
IR 0.93 0.52–1.63 0.792
Menopause, > 50 years
VHR 0.10 0.01–0.82 0.033
HR 0.57 0.25–1.32 0.192
IR 0.55 0.10–3.00 0.489
Abortion, yes
VHR 0.61 0.20–1.85 0.384
HR 0.99 0.59–1.68 0.987
IR 2.63 1.18–5.88 0.018
CHC use, Current/Past
VHR 1.45 0.65–3.25 0.361
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menarche (> 12 years) showed to significantly reduce 
risk for BC in HR women according to previous research. 
Conversely, in our BRCA mutation carriers, menarcheal 
age does not influence BC risk and, interestingly, late 
menopause (> 50 years) seems to be even protective. 
Nevertheless, it should be noted that we excluded from 
the analysis all the patients that developed BC before 
menopause, therefore most of VHR women with BC 
in our sample, decreasing the statistical power of this 
analysis. Interestingly, among women considered for this 
analysis, 50% of women affected by BC went through 
menopause after bilateral (prophylactic or therapeutic) 
oophorectomy before the BC development, while only 
22.2% of women who did not develop BC underwent 
bilateral oophorectomy after the natural menopause. 
However, it should be noted that the tumors developed 
by these women were triple-negative BC. Overall, 
these findings confirm the fact that endogenous ovarian 
hormones are more relevant for estrogen receptor positive 
disease.
Several studies have found that women using oral 
contraceptives have a slightly greater risk of BC than 
women who have never used them. This risk seems to 
go back to normal over time once the pills are stopped. 
Nevertheless, these studies mostly refer to CHC used 
before 1975 and may be the result of exposure to higher 
dosages of estrogens [31, 32]. Moreover, these results have 
been confuted by other studies, showing no association 
between CHC and BC risk. Therefore, different studies 
revealed conflicting results in both general population and 
women at increased familial or genetic BC risk [14]. In 
our study, the current or past use of CHC did not show 
to significantly modify the risk for BC in all the risk 
groups, even if the duration of assumption was longer than 
10 years. One possible implication of these results, along 
with data available in literature, is that chemoprevention 
for ovarian cancer with CHC may be encouraged among 
BRCA mutation carriers.
One of the main limitations of our study consists in 
the lack of data, because several medical records have not 
been entirely filled. As regards tumor characteristics, the 
immune-histochemical features were available only for 
women with invasive carcinomas, diagnosed or treated in 
the province of Modena in the last 20 years, or for women 
who provided their past documentation. Moreover, the 
systematic evaluation of HER2 status became available 
in our Institution only in 2006, when Trastuzumab has 
been approved in the adjuvant setting. Another limitation 
of our study is the non-availability of information 
regarding start age for CHC, breastfeeding and abortion, 
which showed in previous literature to play a role in the 
modulation of BC risk. 
Somewhat unexpectedly, we found different 
risk and protective factors between HR and IR women 
(age at menarche, age at first full term pregnancy and 
miscarriages/abortions). These results may have three 
possible explanations. Firstly, the IR group is smaller and 
with fewer events than the HR group, and this might have 
affected the statistical power of the analyses. Secondly, 
we do not have any information regarding the presence of 
other possible pathogenic mutations in other susceptibility 
genes in this population of women. It is likely that a part 
of these women with positive family history, especially 
in the HR group, may carry an inherited mutation other 
than BRCA, which may have contributed to modify their 
risk of developing BC, irrespectively of the characteristics 
of reproductive life. Finally, women belonging to the 
IR group might have a lower risk perception compared 
to HR risk women, because of their slighter familiarity 
and less intensive surveillance program. Therefore, IR 
women might have worked less hard in order to change 
their modifiable risk factors, such as alcohol assumption, 
tobacco smoking, dietary habits and physical exercise. 
Overall, these missing genetic and lifestyle factors 
represent possible confounders in our analysis.   
Overall, in our study at least one full-term 
pregnancy, breastfeeding and late age (> 50 years) at 
menopause represent the principal protective factors in 
BRCA mutation carriers, while in women at increased 
familial risk early age at first full-term pregnancy and 
late menarche represent the principal protective factors. 
These data are relevant in particular for BRCA mutation 
carriers, which in our sample got fewer pregnancies than 
other women, maybe because of the concern of mutation 
inheritance. These results confirm that pregnancies and the 
reproductive lifespan play crucial roles in the definition 
of BC risk in women at increased familial and genetic 
risk. Moreover, women at high familial risk and mutation 
carries develop tumors with different clinical-pathological 
features and, consequently, are influenced by different 
protective and risk factors. Nevertheless, it is noteworthy 
that in our sample as well as in literature, hormone 
HR 1.03 0.65–1.63 0.901
IR 0.76 0.36–1.58 0.459
CHC Duration, > 10 years
VHR 0.78 0.18–3.34 0.742
HR 1.17 0.65–2.13 0.600
IR 0.56 0.13–2.34 0.424
95% CI = 95% Confidence Interval, VHR = Very High Risk, HR = High Risk, IR = Intermediate Risk.
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receptor negative tumors are mainly associated with 
BRCA1-mutation carriers, while patients with a BRCA2 
mutation seem to develop tumors with histopathological 
profile more similar to that of tumors affecting the general 
population [33, 34]. Therefore, further investigations into 
the correlations among clinical-pathological features and 
reproductive factors in the two different subgroups of 
BRCA-mutation carriers are needed.
MATERIALS AND METHODS
Since 1995, the MFCC classifies women with a 
family history of breast and/or ovarian cancer according 
to the Modena criteria [17, 18] and, more recently, by 
the Tyrer-Cuzick model [35] and provide personalized 
surveillance programs.
The Modena criteria used to classify families are the 
following:
 Criterion 1: At least three relatives with BC in two 
different generations, regardless of family structure. 
Alternatively, two relatives with BC and one 
with OC or one with BC and two with OC in two 
different generations. 
 Criterion 2: At least two family members affected 
by BC with a first-degree relationship. Alternatively, 
one relative with BC and one with OC. In the case 
of male interposition, a relationship of different 
degree (second or third) is allowed. 
 Criterion 3: At least one BC diagnosed before 40 
years of age or bilateral. 
According to these criteria, families are divided into 
main clusters (Table 4): Hereditary Breast (and Ovarian) 
Cancer (HBC/HBOC), Suspected Hereditary Breast 
(and Ovarian) Cancer (SHBC/SHBOC), Familial Breast 
(and Ovarian) Cancer (FBC/FBOC), Suspected Familial 
Breast (and Ovarian) Cancer (SFBC/SFBOC), Strongly 
Suspected Familial Breast (and Ovarian) Cancer (SFBC+/
SFBOC+). 
Together with these basic clusters, some further 
criteria have been added (Table 5): Early Onset Breast 
Cancer (EOBC), Breast and Ovarian Cancer (BOC), Male 
Breast Cancer (MBC), Hereditary Ovarian Cancer (HOC), 
and Familial Ovarian Cancer (FOC). In the absence of any 
criteria, the cases are considered as Sporadic Breast or 
Ovarian Cancer (SpBC/SpOC). 
The characteristics of reproductive life were 
obtained through the revision of the medical records of 
2527 women that started their surveillance program at the 
MFCC between May 2010 and January 2016. Particularly, 
we evaluated number of pregnancies, age at first full-
term pregnancy, breastfeeding, abortions, menarche, 
menopause, and use of combined hormonal contraceptives 
(CHC). Also women with a previous diagnosis of breast 
cancer are admitted to the Center and have been included 
in the present study. The aim of our study was to analyze 
the impact of reproductive history and exogenous 
hormonal exposures in the development of BC in a 
population of BRCA mutation carriers and in women with 
family history of breast and/or ovarian cancer.
At first, women were divided according to a 
combination of the Modena Criteria and the Tyrer-Cuzick 
model in the following three groups: 
Very high risk (VHR)
 women with a recognized BRCA1/2 mutation at the 
genetic testing.
High risk (HR)
 women not tested for BRCA genes or with a non-
informative result, with a 3-fold increased lifetime risk of 
developing BC according to the Tyrer-Cuzick model or 
belonging to HBC/HBOC, SHBC/SHBOC, BOC, HOC, 
and EOBC families according to the Modena criteria.
Intermediate risk (IR)
 women not tested for BRCA genes or with a non-
informative result, not belonging to the High Risk Group, 
with a 2-fold increased lifetime risk of developing BC 
according to the Tyrer-Cuzick model or belonging to 
FBC/FBOC, SFBC/SFBOC, SFBC+/SFBOC+ and MBC 
families according to the Modena criteria.
Women already diagnosed with BC at the time of 
the first access were classified according to the Modena 
Criteria, since the Tyrer-Cuzick model should not be 
applied to affected women. 
Interestingly, the combined classification did not 
show to correctly stratify the cumulative risk at 60 years 
of these women (Figure 1A) and HR women demonstrated 
to have the same cumulative risk of IR women. For this 
reason, we subdivided our population exclusively according 
to the Modena Criteria in the following groups (Figure 1B).
Very high risk (VHR)
women with a recognized BRCA1/2 mutation at the 
genetic testing.
High risk (HR)
women not tested for BRCA genes or with a non-
informative result, belonging to HBC/HBOC, SHBC/
SHBOC, BOC, HOC, and EOBC families.
Intermediate risk (IR)
women not tested for BRCA genes or with a non-
informative result, belonging to FBC/FBOC, SFBC/
SFBOC, SFBC+/SFBOC+ and MBC families.
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Notably, women with a BRCA variant of unknown 
significance (VUS) have been classified according to 
their family history, as current Guidelines recommend. 
One woman with a MLH1 mutation and 3 women who 
underwent bilateral prophylactic mastectomy have been 
excluded from the analyses.
Statistical methods
Since the median age of these women was quite 
low, we decided to evaluate the cumulative risk at 60 
years according to the characteristics of their reproductive 
life. Analyses were conducted separately for subjects 
with mutations and women with a family history of BC 
according to the three risk categories. Unknown data 
(data not provided by women’s medical records) has been 
excluded from the analyses.
In the descriptive analysis, the continuous variables 
were summarized by means of mean and standard 
deviation (SD), and the categorical variables were 
reported as absolute and percent values. Distributions of 
continuous covariates by group were compared using one-
way ANOVA (analysis of variance). The comparison of 
categorical variables between groups was performed using 
the Chi2 test or Fisher’s exact test, when appropriate. The 
cumulative risk to develop BC was calculated from the age 
of menarche to the age of diagnosis of BC, or age of the 
last control for censored patients. The cumulative hazard 
rate was calculated and graphically reported by means 
of Nelson-Aalen estimator [36]. The cumulative hazard 
rates comparison between groups were performed using 
the logrank test. The effect of covariates was reported as 
hazard ratio (HR) with 95% confidence interval (CI 95%), 
estimated from the Cox proportional hazard regression 
[37]. All the reported test were two-sided, and tests with 
conventional p-value < 0.05 were considered significant. 
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Table 4: The modena criteria for classification of hereditary and familial predisposition to breast 
and ovarian cancer
CRITERION 1
three relatives with  
BC/OC in two different 
generations
CRITERION 2
first-degree relationship
CRITERION 3
BC diagnosed before 40 
years or bilateral
CLASSIFICATION
X X X HBC/HBOC
X X
SHBC/SHBOC
X X
X FBC/FBOC
X X SFBC+/SFBOC+
X
SFBC/SFBOC
X
Table 5: The additional modena criteria for classification of hereditary and familial predisposition 
to breast and ovarian cancer
ADDITIONAL CRITERIA CLASSIFICATION
BC diagnosed ≤ 35 years EOBC
BC and OC in the same woman BOC
Male breast cancer MBC
≥ 2 first-degree relatives diagnosed with OC HOC
≥ 2 relatives diagnosed with OC, not HOC FOC
BC/OC without any of the other criteria SpBC/SpOC
Oncotarget10www.impactjournals.com/oncotarget
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